Cushing Disease Clinical Trial
Official title:
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study
Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory. They can be used to define robust diagnostic thresholds for salivary cortisol for the diagnosis of Cushing's syndrome and pseudo-Cushing combining the three tests performed as part of the patient's usual management. (ie two urinary free cortisol (UFC), the dexamethasone suppression test, and Diurnal variation of plasma cortisol).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02350153 -
Cushing´s Disease Epidemiology in Sweden
|
||
| Not yet recruiting |
NCT03297892 -
Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015
|
N/A | |
| Recruiting |
NCT05804669 -
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03364803 -
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
|
||
| Recruiting |
NCT03774446 -
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
|
Phase 2 | |
| Completed |
NCT03080181 -
Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment
|
Phase 4 | |
| Recruiting |
NCT03831958 -
Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
|
||
| Completed |
NCT01331239 -
Safety and Efficacy of LCI699 in Cushing's Disease Patients
|
Phase 2 | |
| Completed |
NCT04201444 -
Hair Cortisol and Cushing's Disease
|
N/A | |
| Completed |
NCT02233335 -
The Factors Associated With the Recurrence in Patients With Cushing Disease
|
N/A | |
| Recruiting |
NCT04374721 -
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
|
N/A | |
| Completed |
NCT03621280 -
Open-label Treatment in Cushing's Syndrome
|
Phase 3 | |
| Not yet recruiting |
NCT05971758 -
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
|
Phase 2 | |
| Recruiting |
NCT04486859 -
Postoperative Thrombosis Prevention in Patients With CD
|
N/A | |
| Completed |
NCT00171951 -
Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
|
Phase 2 | |
| Recruiting |
NCT00001595 -
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
|